This article is more than 5 years old. Information may no longer be current.

IND active for wet AMD treatment from Regenxbio

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

An investigational new drug application is now active for a phase 1 trial of the wet age-related macular degeneration treatment RGX-314, according to a press release from Regenxbio.

The multicenter, open-label, multiple-cohort, dose-escalation trial is expected to begin enrolling patients mid-year, with an interim update expected by the end of the year.

“The goal of the RGX-314 program is to develop a single-dose treatment for wet AMD that prevents future disease recurrence while reducing or eliminating the need for regular injections that are the current standard of care in wet AMD,” Kenneth T. Mills, president and CEO of Regenxbio, said in the release.

Approximately 18 subjects who have been previously treated with wet AMD therapy are expected to be enrolled in the trial, which will study the safety and tolerability of RGX-314 at 24 weeks after a single dose.